💊 What the Company Does
Gilead Sciences is a global biopharmaceutical company focused on medicines for serious diseases. Its main areas include HIV treatment, liver disease, oncology, and other specialty therapies.
In plain English, Gilead is best known for its strong HIV drug business, while cancer treatments represent an important area for future growth.
📊 Financial Highlights
Gilead reported $29,443m in revenue for FY 2025, up from $28,754m in FY 2024. Net income recovered sharply to $8,510m, compared with $480m in FY 2024.
- Revenue: $29,443m in FY 2025
- Operating income: $10,022m in FY 2025
- Diluted EPS: $6.8 in FY 2025
- Operating cash flow: $10,019m in FY 2025
The main takeaway is that FY 2024 earnings were pressured by large development-related costs, while FY 2025 showed a strong profitability rebound.
⚠️ Key Risks
Gilead’s key risks are closely tied to the pharmaceutical industry. The company depends on successful drug development, regulatory approvals, patent protection, product safety, and payer coverage.
- Drug development risk: New medicines may fail in trials or face approval delays.
- Competition risk: Rival drugs, generics, or biosimilars may reduce sales.
- Pricing and reimbursement risk: Insurers and government programs may pressure drug prices.
- Pipeline risk: Future growth depends on successful new therapies.
For beginners, the key point is simple: Gilead’s current business is profitable, but long-term performance depends on maintaining strong products and developing new ones.
🧭 MD&A Summary
Management highlighted continued strength in the company’s core HIV portfolio and growth from oncology products. FY 2025 operating performance improved mainly because large development-related expenses and impairments were lower than in FY 2024.
Gilead also continued to generate strong cash flow, which supported research and development, acquisitions, dividends, share repurchases, and debt management.
✅ Takeaway
Gilead Sciences combines a stable, cash-generating HIV business with efforts to expand in oncology and new drug development. FY 2025 showed stronger profitability and cash flow after an unusually weak FY 2024 earnings year.
For beginner investors, the company can be understood as a mature biopharmaceutical business with strong current cash flow, but with future results tied to drug innovation, competition, regulation, and pricing access.
Income Statement Summary 💵
Values are shown in $m, except EPS in dollars.
| (Unit: $m, EPS in $) | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | 27,116 | 28,754 | 29,443 |
| Cost of Goods Sold | 6,498 | 6,251 | 6,234 |
| Gross Profit | 20,618 | 22,503 | 23,209 |
| SG&A | 6,090 | 6,091 | 5,774 |
| Operating Income | 7,605 | 1,662 | 10,022 |
| Non-Operating Income/Expense | 198 | 6 | 798 |
| Interest Income/Expense | (944) | (977) | (1,024) |
| Income Before Tax | 6,859 | 690 | 9,796 |
| Income Tax | 1,247 | 211 | 1,286 |
| Net Income | 5,665 | 480 | 8,510 |
| EPS | 4.5 | 0.4 | 6.8 |
Plain English: Gilead’s revenue increased from $27,116m in FY 2023 to $29,443m in FY 2025. The bigger change was profitability. FY 2024 operating income fell sharply because of large acquired in-process research and development expenses and impairments, which are costs tied to drug assets still in development. In FY 2025, operating income recovered to $10,022m, showing that the company’s core business remained highly profitable once those unusual development-related charges were much lower.
Profitability and Balance Sheet Ratios 📈
Percentages are rounded to one decimal place.
| Ratio | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| ROE (%) | 24.9% | 2.5% | 37.6% |
| ROA (%) | 9.1% | 0.8% | 14.4% |
| ROTC (%) | 15.9% | 3.6% | 21.1% |
| ROIC (%) | 14.9% | 3.2% | 21.8% |
| Gross Margin (%) | 76.0% | 78.3% | 78.8% |
| Operating Margin (%) | 28.0% | 5.8% | 34.0% |
| Pretax Margin (%) | 25.3% | 2.4% | 33.3% |
| Net Margin (%) | 20.9% | 1.7% | 28.9% |
| Debt-to-Equity Ratio (D/E) (%) | 109.8% | 138.8% | 110.2% |
| Net Debt / EBITDA (x) | 1.8x | 3.8x | 1.4x |
| Interest Coverage Ratio (x) | 8.1x | 1.7x | 9.8x |
| Current Ratio (%) | 142.6% | 159.7% | 155.3% |
| Quick Ratio (%) | 105.7% | 120.1% | 106.2% |
| Fixed Asset to Long-term Capital Ratio (%) | 11.6% | 12.3% | 12.5% |
Plain English: FY 2025 shows a clear profitability rebound. Gilead’s gross margin improved to 78.8%, meaning the company kept a large share of revenue after product production costs. More importantly, operating margin rose to 34.0%, compared with only 5.8% in FY 2024. The improvement also strengthened return metrics: ROIC increased to 21.8%, which means the business generated stronger operating profit relative to the capital invested in the company. Leverage also looked more manageable in FY 2025, as Net Debt / EBITDA improved to 1.4x from 3.8x in FY 2024.
📝 Disclaimer
This article is intended for educational purposes only. It does not constitute financial, investment, or legal advice. All investment decisions involve risks, and readers should conduct their own research or consult with a licensed financial advisor.
👉 Gilead Sciences (GILD) FY 2025 10-K Analysis (Filed 2026) | Explained for Beginners
Originally published on Finvincio